1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7–34.
Google Scholar | Crossref | Medline2. Pan, J, Song, G, Chen, D, et al. Identification of serological biomarkers for early diagnosis of lung cancer using a protein array-based approach. Mol Cell Proteomics 2017; 16: 2069–2078.
Google Scholar | Crossref | Medline3. Dal Bello, MG, Filiberti, RA, Alama, A, et al. The role of CEA, CYFRA21–1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med 2019; 17: 74.
Google Scholar | Crossref | Medline4. Kato, Y, Tanaka, Y, Hino, M, et al. ProGRP as early predictive marker of non–small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment. Respir Med Case Reports 2019; 27: 100837.
Google Scholar | Crossref | Medline5. Cavalieri, S, Morelli, D, Martinetti, A, et al. Clinical implications for pro-GRP in small cell lung cancer. A single center experience. Int J Biol Markers 2018; 33: 55–61.
Google Scholar | SAGE Journals | ISI6. Matoušek, P, Zeleník, K, Safarčík, K, et al. Squamous cell carcinoma antigen as a marker of sinonasal inverted papilloma. Eur Arch Otorhinolaryngol 2014; 271: 535–538.
Google Scholar | Crossref | Medline7. Tan, F, Jiang, Y, Sun, N, et al. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol Cell Proteomics 2012; 11:M111.008821. DOI: 10.1074/mcp.M111.008821.
Google Scholar | Crossref8. Sun, N, Sun, S, Gao, Y, et al. Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non-small-cell lung cancer: A multicenter in vitro diagnostic clinical trial. Cancer Sci 2020; 111: 1739–1749. DOI: 10.1111/cas.14387.
Google Scholar | Crossref9. Avellaneda Matteo, D, Grunseth, AJ, Gonzalez, ER, et al. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency. J Biol Chem 2017; 292: 7971–7983.
Google Scholar | Crossref | Medline10. Dang, L, White, DW, Gross, S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739–744.
Google Scholar | Crossref | Medline | ISI11. Han, S, Liu, Y, Cai, SJ, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer 2020; 122: 1580–1589.
Google Scholar | Crossref | Medline12. Wu, J, Wang, F, Liu, X, et al. Correlation of IDH1 and B7–H3 expression with prognosis of CRC patients. Eur J Surg Oncol 2018; 44: 1254–1260. DOI: 10.1016/j.ejso.2018.05.005.
Google Scholar | Crossref13. Chen, X, Li, Q, Wang, C, et al. Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma. Oncotarget 2016; 7: 86148–86160. DOI: 10.18632/oncotarget.13351.
Google Scholar | Crossref14. Bai, M, Yang, L, Liao, H, et al. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism. Oncogene 2018; 37: 5666–5681. DOI: 10.1038/s41388-018-0360-7.
Google Scholar | Crossref15. Khurshed, M, Aarnoudse, N, Hulsbos, R, et al. IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity. FASEB J 2018; 32: fj201800547R. DOI: 10.1096/fj.201800547R.
Google Scholar | Crossref16. Zhang, J, Bajari, R, Andric, D, et al. The International Cancer Genome Consortium Data Portal. Nat Biotechnol 2019; 37: 367–369.
Google Scholar | Crossref | Medline17. Tang, Z, Li, C, Kang, B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45: W98–W102.
Google Scholar | Crossref | Medline18. Ou, F-S, Michiels, S, Shyr, Y, et al. Biomarker discovery and validation: statistical considerations. J Thorac Oncol 2021; 16: 537–545.
Google Scholar | Crossref | Medline19. Sun, N, Chen, Z, Tan, F, et al. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. Clin Cancer Res 2013; 19: 5136–5145. DOI: 10.1158/1078-0432.CCR-13-0046.
Google Scholar | Crossref20. Zhang, Q, Qu, H, Sun, G, et al. Early postoperative tumor marker responses provide a robust prognostic indicator for N3 stage gastric cancer. Medicine (Baltimore) 2017; 96: e7560.
Google Scholar21. Wang, Y, Yin, W, Lin, Y, et al. Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer. Cell death Discov 2018; 4: 21.
Google Scholar | Crossref22. DiNardo, CD, Stein, EM, de Botton, S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018; 378: 2386–2398.
Google Scholar | Crossref | Medline23. Molenaar, RJ, Maciejewski, JP, Wilmink, JW, et al. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene 2018; 37: 1949–1960.
Google Scholar | Crossref | Medline